Work package 2: Development and validation of immunological assays to assess immune response following vaccination with ShigOraVax
Led by University of Gothenburg, Sweden
The main objective of this work package is to set up and validate assays for the immunogenicity analysis following vaccination with ShigOraVax in participants of the clinical trials in Europe and Africa. The specific objectives are to:
Establish human serum antibody assays (to be used in phase Ia/Ib in Europe and Africa and in phase II and phase IIb in Africa)
Establish human fecal antibody assays (phase Ia/Ib in Europe and Africa)
Establish human intestinal mucosal immune response assays – ALS antibodies from intestine-derived B cells (phase Ia in Europe).
Transfer of the assays to the partners